A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)

David E. Griffith (Tyler, United States of America), David Griffith, Patrick Flume, Kevin Winthrop, Rachel Thomson, Dirk Wagner, Jakko Van Ingen, Liza Micioni, John P. McGinnis II, Carlos Fernandez, Gina Eagle

Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Session: Novel strategies for the management of asthma, COPD and airway infections
Session type: Thematic Poster Session
Number: 3945
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
David E. Griffith (Tyler, United States of America), David Griffith, Patrick Flume, Kevin Winthrop, Rachel Thomson, Dirk Wagner, Jakko Van Ingen, Liza Micioni, John P. McGinnis II, Carlos Fernandez, Gina Eagle. A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC). Eur Respir J 2015; 46: Suppl. 59, 3945

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: